Dublin-based pharma company Elan saw its share price shoot up after its chairman said that its multiple sclerosis treatment Tysabri may become a $3 billion drug.
At 1500 the shares were trading up 2.8 per cent while the broader market was up one per cent.
Speaking at the company’s AGM, Robert Ingram also said that he expects probable clarity this year on the company’s Alzheimer’s compound Bapineuzumab. Elan collaborates on that drug with Pfizer in a 50:50 joint...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team